Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Metabolic syndrome implicated in hidradenitis suppurativa

06 Jul 2019

Hidradenitis suppurativa (HS) carries about a twofold increased likelihood of having metabolic syndrome, according to the results of a meta-analysis.

Researchers searched multiple online databases for studies comparing patients with HS vs non-HS controls. All studies must have included either the number of patients with metabolic syndrome in each group or the magnitude of association between HS and metabolic syndrome.

The meta-analysis included six case–control studies, all of which had moderate level of evidence, with total scores on the Newcastle-Ottawa scale ranging between 6 and 7 out of 9.

Pooled data revealed metabolic syndrome to be significantly more common in the HS group than in the control group (odds ratio [OR], 1.95, 95 percent CI, 1.31–2.89; p=0.001; I2, 81 percent). The association between HS and metabolic syndrome persisted even after controlling for age, sex, other cardiovascular risk factors and comorbidities (OR, 2.19, 1.70–2.81; p<0.00001; I2, 32 percent).

While it remains to be established whether there exists a causal relationship—whether the chronic inflammatory nature of HS can trigger development of metabolic syndrome or whether associated features of metabolic syndrome predispose patients to develop HS—the researchers postulated that metabolic syndrome-related obesity may predispose to HS via follicular occlusion and the significantly higher amount of adipose cells, which produce inflammatory cytokines.

Nevertheless, the researchers stressed that clinicians managing patients with HS should be aware of the condition’s potential association with metabolic syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.